List of Barhemsys drug patents

Barhemsys is owned by Acacia.

Barhemsys contains Amisulpride.

Barhemsys has a total of 5 drug patents out of which 0 drug patents have expired.

Barhemsys was authorised for market use on 26 February, 2020.

Barhemsys is available in solution;intravenous dosage forms.

Barhemsys can be used as treatment of post-operative nausea and vomiting; prevention of post-operative nausea and vomiting, treatment of post-operative nausea and vomiting, prevention of post-operative nausea and vomiting; treatment of post-operative nausea and vomiting.

Drug patent challenges can be filed against Barhemsys from February, 2024.

The generics of Barhemsys are possible to be released after 09 February, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9545426 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(8 years from now)

US9889118 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(8 years from now)

US10525033 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(8 years from now)

US9084765 ACACIA Use of amisulpride as an anti-emetic
Feb, 2034

(11 years from now)

US11357753 ACACIA Rescue treatment of post operative nausea and vomiting
Feb, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Prevention of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in